CDKN2A and acute lymphoblastic leukemia: We also found that the incidence of CDKN2A/B deletion was significantly higher (52.6% vs. 33.9%, P=0.064) in these patients, and it was a poor prognostic factor in MRD-positive Ph-B-ALL, regardless of HSCT.